Status:

UNKNOWN

Randomised Double-blind Active vs. Placebo Clinical Trial on the Effect of a Food Supplement on IBS in Children

Lead Sponsor:

Azienda Ospedaliera Universitaria Policlinico "G. Martino"

Conditions:

Irritable Bowel Syndrome

Eligibility:

All Genders

3-17 years

Phase:

NA

Brief Summary

The goal of this clinical trial is to test a food supplement in children of 3-17 years with IBS. The main questions it aims to answer are: * Is the tested supplement able to improve and/or reduce IBS...

Detailed Description

Irritable Bowel Syndrome (IBS) is a functional gastrointestinal disorder characterised essentially by abdominal pain and alterations in bowel movements. IBS is linked to a sensory and intestinal motor...

Eligibility Criteria

Inclusion

  • Subjects presenting symptoms of IBS according to Rome IV criteria.
  • Presence of functional disorders according to assessment questionnaire with a score of 2 or more.
  • Age between 3 and 17 years and 11 months.
  • Willingness of the subject/parent to participate in the study.
  • Willingness of the subject/parent to complete the questionnaire.
  • Willingness of subject/parent to use only the product to be tested during the duration of the study.
  • Willingness of the subject/parent not to use similar products during the duration of the study.
  • Parent's signature of informed consent.

Exclusion

  • Subjects who do not meet the inclusion criteria.
  • Subjects considered unfit by the referring physician.
  • Subjects with suspected or confirmed sensitivity to one or more components of the product.
  • Subjects with psychiatric comorbidities.
  • Subjects with serious illnesses.
  • Subjects with differential diagnoses (functional dyspepsia, coeliac disease, IBD, food intolerances, individual hypersensitivities).
  • Subjects undergoing ongoing pharmacological treatment, inherent to the disease (e.g. spasmolytics etc.).
  • Subjects who have recently (two weeks or less) undergone antibiotic therapy
  • Subjects with other concomitant diseases (immune, infectious, respiratory or gastro-intestinal).
  • Subjects with growth restriction.
  • Subjects with congenital malformations.

Key Trial Info

Start Date :

April 1 2023

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

April 1 2025

Estimated Enrollment :

128 Patients enrolled

Trial Details

Trial ID

NCT06123234

Start Date

April 1 2023

End Date

April 1 2025

Last Update

July 16 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gioacchino Calapai

Messina, Italy, 98125